Edition:
India

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

5.29USD
9 Dec 2019
Change (% chg)

-- (--)
Prev Close
$5.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
88,129
52-wk High
$9.23
52-wk Low
$2.12

Latest Key Developments (Source: Significant Developments)

Chiasma Posts Q3 Loss Per Share Of $0.20
Wednesday, 6 Nov 2019 

Nov 5 (Reuters) - Chiasma Inc ::CHIASMA REPORTS THIRD QUARTER 2019 RESULTS.Q3 LOSS PER SHARE $0.20.Q3 EARNINGS PER SHARE ESTIMATE $-0.21 -- REFINITIV IBES DATA.CHIASMA OPTIMAL TRIAL, CONDUCTED UNDER SPA AND DESIGNED TO SUPPORT FDA APPROVAL, MET PRIMARY AND ALL SECONDARY ENDPOINTS.MYCAPSSA® NDA ON TRACK FOR SUBMISSION BY YEAR-END 2019.MPOWERED(TM) PHASE 3 TRIAL, DESIGNED TO SUPPORT EU APPROVAL, PROGRESSING AS PLANNED WITH TOPLINE DATA EXPECTED IN 2H 2020.  Full Article

Chiasma Files For Mixed Shelf Of Up To $200 Million
Saturday, 7 Sep 2019 

Sept 6 (Reuters) - Chiasma Inc ::CHIASMA FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING.  Full Article

Chiasma Reports Q2 Loss Per Share $0.25
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Chiasma Inc ::CHIASMA REPORTS SECOND QUARTER 2019 RESULTS.Q2 LOSS PER SHARE $0.25.Q2 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.  Full Article

Chiasma Announces Proposed Offering Of Common Stock
Friday, 26 Jul 2019 

July 25 (Reuters) - Chiasma Inc ::CHIASMA ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.CHIASMA INC - INTENDS TO USE NET PROCEEDS FROM OFFERING PRIMARILY FOR COMMERCIALIZATION OF MYCAPSSA IN UNITED STATES, IF APPROVED.  Full Article

Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa For The Maintenance Treatment Of Adults With Acromegaly
Tuesday, 23 Jul 2019 

July 23 (Reuters) - Chiasma Inc ::CHIASMA ANNOUNCES POSITIVE PHASE 3 TOP-LINE RESULTS FROM CHIASMA OPTIMAL CLINICAL TRIAL OF MYCAPSSA® FOR THE MAINTENANCE TREATMENT OF ADULTS WITH ACROMEGALY.CHIASMA INC - NO NEW OR UNEXPECTED SAFETY SIGNALS IN MYCAPSSA TREATED PATIENTS.CHIASMA INC - NO NEW OR UNEXPECTED SAFETY SIGNALS IN MYCAPSSA TREATED PATIENTS.CHIASMA INC - SPA-AGREED TRIAL MET PRIMARY AND ALL SECONDARY ENDPOINTS.CHIASMA INC - 90% OF PATIENTS TREATED WITH MYCAPSSA WHO COMPLETED 36-WEEK STUDY OPTED TO CONTINUE INTO OPEN LABEL EXTENSION.CHIASMA INC - SPA-AGREED TRIAL MET PRIMARY AND ALL SECONDARY ENDPOINTS.CHIASMA INC - IN CHIASMA OPTIMAL TRIAL, OCTREOTIDE CAPSULES APPEARED SAFE AND WELL TOLERATED.CHIASMA - PLANS TO SUBMIT NDA BY END OF YEAR FOR OCTREOTIDE CAPSULES FOR MAINTENANCE TREATMENT OF ADULTS WITH ACROMEGALY.CHIASMA INC - ENDED JUNE 30, 2019 WITH APPROXIMATELY $58.1 MILLION IN CASH AND INVESTMENTS AS COMPARED TO $41.7 MILLION AT DECEMBER 31, 2018..  Full Article

Chiasma Strengthens Leadership Team Ahead Of Anticipated Commercial Availability Of Mycapssa
Thursday, 6 Jun 2019 

June 5 (Reuters) - Chiasma Inc ::CHIASMA STRENGTHENS LEADERSHIP TEAM AHEAD OF ANTICIPATED COMMERCIAL AVAILABILITY OF MYCAPSSA®.CHIASMA INC - APPOINTS PHARMA COMMERCIAL VETERAN RAJ KANNAN AS CHIEF EXECUTIVE OFFICER.CHIASMA INC - CURRENT CEO MARK FITZPATRICK TO RETAIN ROLE OF PRESIDENT.CHIASMA INC - MANAGEMENT TRANSITION IS EXPECTED TO BE EFFECTIVE NO LATER THAN JUNE 17, 2019..  Full Article

Chiasma Q1 Loss Per Share $0.36
Friday, 10 May 2019 

May 9 (Reuters) - Chiasma Inc ::CHIASMA REPORTS FIRST QUARTER 2019 RESULTS.Q1 LOSS PER SHARE $0.36.Q1 EARNINGS PER SHARE ESTIMATE $-0.34 -- REFINITIV IBES DATA.ADVANCING ITS ONGOING MULTI-NATIONAL MPOWERED™ PHASE 3 TRIAL.ENDED QUARTER WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $33.9 MILLION.  Full Article

Chiasma - Chiasma Optimal Phase 3 Topline Data Expected In Q3 2019
Friday, 4 Jan 2019 

Jan 3 (Reuters) - Chiasma Inc ::CHIASMA INC - CHIASMA OPTIMAL PHASE 3 TOPLINE DATA EXPECTED IN Q3 2019.CHIASMA INC - ANTICIPATES SUBMITTING U.S. NDA BY YEAR-END 2019, ASSUMING POSITIVE CHIASMA OPTIMAL DATA.CHIASMA INC - PLAN FOR POSSIBLE FDA APPROVAL OF MYCAPSSA IN MID-2020.CHIASMA - ANTICIPATES CURRENT CASH BALANCE IS SUFFICIENT TO FUND OPERATIONS AS PLANNED THROUGH CHIASMA OPTIMAL TOPLINE DATA & INTO EARLY 2020.  Full Article

Chiasma Q3 Loss Per Share $0.31
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Chiasma Inc ::CHIASMA REPORTS THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.31.CHIASMA - RANDOMIZES 80(TH) PATIENT IN PHASE 3 MPOWERED TRIAL OF OCTREOTIDE CAPSULES, ELECTS TO RESUME ENROLLMENT OF UP TO ADDITIONAL 15 U.S. PATIENTS.CHIASMA - CASH SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST ANTICIPATED RELEASE OF TOP-LINE CHIASMA OPTIMAL DATA WHILE SUPPORTING MPOWERED TRIAL.DECISION TO RESUME ENROLLMENT INTO MPOWERED TRIAL HAS NO EXPECTED IMPACT ON ONGOING CHIASMA OPTIMAL TRIAL.  Full Article

Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial
Tuesday, 15 May 2018 

May 14 (Reuters) - Chiasma Inc ::CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL.CHIASMA - FOURTH, FIFTH SECONDARY ENDPOINTS IN PHASE 3 TRIAL NOW BEEN REDEFINED TO DESCRIPTIVE STATISTICS MEASURED WITHIN EACH TREATMENT GROUP.CHIASMA INC - UNDER SPA AGREEMENT MODIFICATION FOR CHIASMA OPTIMAL PHASE 3 TRIAL, BETWEEN-ARM COMPARISONS OF 2 DESCRIPTIVE MEASURES WILL NOT BE MADE.CHIASMA INC - FDA INDICATED IT PLANS TO CONSIDER SECONDARY ENDPOINTS IN ITS EVALUATION OF TOTALITY OF EVIDENCE OF ORAL OCTREOTIDE'S TREATMENT EFFECT.  Full Article